Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline Effects on PAI-1 in Obesity
NCT00770328Phase 4Completed
- Sponsor
- Vanderbilt University
- Start
- May 2003
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Pentoxifylline with Placebo (2 arms). Primary endpoint: Change in Plasminogen Activator Inhibitor-1 Level at 8 weeks. Started May 2003; status: completed.
02
Drugs
pentoxifylline
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00770328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770328.